LIVE
NTLA
Intellia Therapeutics, Inc. · Health Care - In Vivo Gene Editing
$15.67
+31.24% this month
VERSUS
⟷
COMPARE
CRSP
CRISPR Therapeutics AG · Health Care - Gene Editing
$54.09
+13.66% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
NTLA
2
CRSP
2
Comparison scoreboard
MIXED SETUPAI Score
NTLA 25.0
CRSP ✓34.4
1Y Return
NTLA ✓+63.23%
CRSP +21.74%
Fwd P/E
NTLA -8.70
CRSP ✓-14.12
Target Up.
NTLA ✓+69.95%
CRSP +54.42%
Op. Margin
NTLA N/A
CRSP N/A
Metrics last refreshed: 6/20/2026
Quick take
NTLA vs CRSP Stock Comparison: AI Score, Valuation, Performance and Upside
NTLA and CRSP are both leading CRISPR gene editing companies but with different strategic approaches — NTLA is furthest along in developing in vivo CRISPR therapies (directly editing cells inside the body), while CRSP has the first approved CRISPR therapy (ex vivo) and is now also developing in vivo programs. Intellia's in vivo data in ATTR amyloidosis has been particularly impressive clinically.
NTLA vs CRSP compares two CRISPR leaders at different points in their gene editing journeys, with Intellia advancing potentially transformative in vivo data and CRISPR Therapeutics leveraging its first-approved-therapy status into next-generation programs.
Live analysis · updated 6/20/2026
NTLA and CRSP are closely matched — they split the tracked metrics evenly. NTLA has delivered stronger 1-year price return (+63.23% vs +21.74%), though CRSP trades at the lower forward P/E (-14.12x vs -8.70x). Analyst consensus implies meaningfully more upside for NTLA (+69.95%) than for CRSP (+54.42%).
Normalized 1Y performance
NTLA
CRSP
Recent returns
NTLA
CRSP
Analyst price targets & sentiment
NTLA · 19 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.1/5.0)
Price target range
analyst low$8.00
analyst high$95.00
analyst mean$26.63
current price$15.67
+70.0% upside to analyst mean
CRSP · 21 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$44.00
analyst high$291.00
analyst mean$83.52
current price$54.09
+54.4% upside to analyst mean
Who should consider this stock?
NTLA may suit investors who:
- →Want exposure to the potential first approved in vivo CRISPR gene editing therapy
- →Believe in vivo gene editing will ultimately address larger patient populations than ex vivo approaches
- →Find Intellia's ATTR amyloidosis clinical data particularly compelling
CRSP may suit investors who:
- →Value CRISPR Therapeutics' proven track record of bringing the first CRISPR therapy to approval
- →Value the financial and commercial support from the Vertex partnership
- →Want gene editing exposure with a commercially approved product rather than pre-commercial programs only
Performance & AI score
| Metric | NTLA | CRSP |
|---|---|---|
| AI score | 25.0 | 34.4 |
| AI rank | #2893 | #1740 |
| Latest close | $15.67 | $54.09 |
| 1M return | +31.24% | +13.66% |
| 6M return | +78.27% | -1.19% |
| 1Y return | +63.23% | +21.74% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NTLA | CRSP |
|---|---|---|
| 1Y ago | $16.32K (+63.2%) started 2025-06-18 | $12.17K (+21.7%) started 2025-06-18 |
| 5Y ago | $2.06K (-79.4%) started 2021-06-18 | $4.23K (-57.7%) started 2021-06-18 |
| 10Y ago | $5.68K (-43.2%) started 2016-06-20 | $38.39K (+283.9%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | NTLA | CRSP |
|---|---|---|
| Market cap | $2.19B | $5.33B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -8.70 | -14.12 |
| Price/Sales | 33.13 | 1298.32 |
| EV/Revenue | 26.29 | 819.67 |
| Analyst target | $26.63 | $83.52 |
| Target upside | +69.95% | +54.42% |
Growth, profitability & risk
| Metric | NTLA | CRSP |
|---|---|---|
| Revenue growth | -9.50% | 68.60% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -355.92% | -6358.66% |
| Operating margin | N/A | N/A |
| Profit margin | 0.00% | 0.00% |
| ROIC proxy | -56.34% | -31.21% |
| Return on equity | -56.34% | -31.21% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 1.81 | 1.70 |
| Debt/equity | 12.96 | 43.41 |
| Current ratio | 6.10 | 17.96 |
| Quick ratio | 5.04 | 17.92 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
NTLA max drawdown71.27%
CRSP max drawdown42.25%
NTLA max wkly drop52.63%
CRSP max wkly drop17.63%
5Y risk snapshot
NTLA max drawdown96.45%
CRSP max drawdown80.68%
NTLA max wkly drop52.63%
CRSP max wkly drop21.49%
10Y risk snapshot
NTLA max drawdown96.45%
CRSP max drawdown85.11%
NTLA max wkly drop52.63%
CRSP max wkly drop30.47%
Performance metrics by period
| Period | Metric | NTLA | CRSP |
|---|---|---|---|
| 1Y | Growth | +63.23% | +21.74% |
| CAGR | +63.28% | +21.76% | |
| Sharpe ratio | 0.98 | 0.55 | |
| Max drawdown | 71.27% | 42.25% | |
| Max daily drop | 42.23% | 11.59% | |
| Max wkly drop | 52.63% | 17.63% | |
| 5Y | Growth | -79.36% | -57.69% |
| CAGR | -27.07% | -15.80% | |
| Sharpe ratio | -0.04 | -0.06 | |
| Max drawdown | 96.45% | 80.68% | |
| Max daily drop | 42.23% | 13.32% | |
| Max wkly drop | 52.63% | 21.49% | |
| 10Y | Growth | -43.25% | +283.89% |
| CAGR | -5.51% | +14.94% | |
| Sharpe ratio | 0.26 | 0.46 | |
| Max drawdown | 96.45% | 85.11% | |
| Max daily drop | 42.23% | 17.10% | |
| Max wkly drop | 52.63% | 30.47% |
Business comparison
| Category | NTLA | CRSP |
|---|---|---|
| Company | Intellia Therapeutics, Inc. | CRISPR Therapeutics AG |
| Sector | Health Care - In Vivo Gene Editing | Health Care - Gene Editing |
| Industry | N/A | N/A |
| Core business | Intellia Therapeutics focuses on developing in vivo CRISPR gene editing medicines — directly delivering gene editing tools into patients' bodies to correct disease-causing genetic mutations — with lead programs in ATTR amyloidosis and hemophilia A. | CRISPR Therapeutics developed Casgevy, the first FDA-approved CRISPR therapy (for sickle cell disease and beta-thalassemia), in partnership with Vertex Pharmaceuticals, while advancing next-generation in vivo programs in cardiovascular disease. |
| Investor focus | Investors track Intellia's pivotal clinical trial progress for NTLA-2001 (in vivo ATTR amyloidosis) and NTLA-2002, which could represent the first approved in vivo CRISPR therapies if successful. | Investors track Casgevy commercial ramp, next-generation in vivo cardiovascular programs, and the overall gene editing pipeline development supported by Vertex partnership funding. |
NTLA strengths
- →Pioneer and potential leader in in vivo CRISPR gene editing, a potentially broader and simpler approach than ex vivo
- →ATTR amyloidosis program (NTLA-2001) has shown impressive clinical data suggesting single-treatment durability
- →Broadly licensed Cas9 platform from foundational Feng Zhang/MIT IP estate
CRSP strengths
- →Only publicly traded gene editing company with a commercially approved CRISPR therapy (Casgevy)
- →Well-funded through Vertex partnership with substantial cash runway
- →Expanding into in vivo CRISPR programs that could address much larger patient populations than sickle cell/beta-thal
Risks to watch — NTLA
- →All programs are still clinical-stage; no commercially approved products yet
- →In vivo CRISPR delivery into the liver has been demonstrated but delivery into other tissues remains technically challenging
- →Competing against strong ATTR amyloidosis drugs already approved (Alnylam, Ionis)
Risks to watch — CRSP
- →Casgevy commercial adoption slower than initially expected due to treatment complexity
- →Ex vivo gene editing approach is complex and resource-intensive for both patients and treatment centers
- →In vivo programs are still early-stage and have not yet demonstrated clinical proof-of-concept
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →